{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:11:07Z","timestamp":1793034667290,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study is to evaluate risk factors for severe coronavirus disease 2019 (COVID-19) in patients with immune-mediated rheumatic diseases, stratified by systemic autoimmune conditions and chronic inflammatory arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational, cross-sectional multicentre study was performed. Patients from 10 rheumatology departments in Madrid who presented with severe acute respiratory syndrome coronavirus-2 infection between February 2020 and May 2021 were included. The main outcome was COVID-19 severity (hospital admission or mortality). Risk factors for severity were estimated, adjusting for covariates (socio-demographic, clinical, and treatments), using logistic regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 523 patients with COVID-19 were included, among whom 192 (35.6%) patients required hospital admission and 38 (7.3%) died. Male gender, older age, and comorbidities such as diabetes mellitus, hypertension, and obesity were associated with severe COVID-19. Corticosteroid doses &amp;gt;10\u2009mg\/day, rituximab, sulfasalazine, and mycophenolate use, were independently associated with worse outcomes. COVID-19 severity decreased over the different pandemic waves. Mortality was higher in the systemic autoimmune conditions (univariate analysis, P\u2009&amp;lt;\u2009.001), although there were no differences in the overall severity in the multivariate analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirms and provides new insights regarding the harmful effects of corticosteroids, rituximab, and other therapies (mycophenolate and sulfasalazine) in COVID-19. Methotrexate and anti-tumour necrosis factor therapy were not associated with worse outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac148","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T18:45:47Z","timestamp":1671043547000},"page":"97-105","source":"Crossref","is-referenced-by-count":9,"title":["Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry"],"prefix":"10.1093","volume":"34","author":[{"given":"Alina","family":"Boteanu","sequence":"first","affiliation":[{"name":"Rheumatology Department and IRYCIS, Hospital Universitario Ram\u00f3n y Cajal , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-0545","authenticated-orcid":false,"given":"Leticia","family":"Leon","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos , Madrid, Spain"},{"name":"Health Sciences, Universidad Camilo Jos\u00e9 Cela , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"P\u00e9rez Esteban","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rabad\u00e1n Rubio","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Pr\u00edncipe de Asturias , Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pav\u00eda Pascual","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario La Paz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bonilla Gonz\u00e1lez-Lagan\u00e1","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario del Tajo , Aranjuez, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antia","family":"Garc\u00eda Fernandez","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IRYCIS, Hospital Universitario Ram\u00f3n y Cajal , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Recuero Diaz","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ruiz Gutierrez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Pr\u00edncipe de Asturias , Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Javier","family":"Sanmart\u00edn Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Severo Ochoa , Leganes, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"de la Torre-Rubio","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario La Paz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"S\u00e1nchez Pernaute","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"del Bosque","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IRYCIS, Hospital Universitario Ram\u00f3n y Cajal , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Lojo Oliveira","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Infanta Leonor , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Rodr\u00edguez Heredia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario de Getafe , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Clemente","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Infantil Ni\u00f1o Jesus , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Abasolo","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bachiller-Corral","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IRYCIS, Hospital Universitario Ram\u00f3n y Cajal , Madrid, Spain"},{"name":"Universidad de Alcal\u00e1 , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"2023122314260824800_R1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMp2002106","article-title":"Escaping Pandora\u2019s box \u2013 another novel coronavirus","volume":"382","author":"Morens","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122314260824800_R2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0243262","article-title":"COVID-19 mortality risk assessment: an international multi-center study","volume":"15","author":"Bertsimas","year":"2020","journal-title":"PLoS One"},{"key":"2023122314260824800_R3","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2665-9913(21)00112-0","article-title":"SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study","volume":"3","author":"Saadoun","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023122314260824800_R4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R5","doi-asserted-by":"crossref","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","article-title":"Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark","volume":"60","author":"Cordtz","year":"2021","journal-title":"Rheumatol"},{"key":"2023122314260824800_R6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00296-021-04803-9","article-title":"Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis","volume":"41","author":"Wang","year":"2021","journal-title":"Rheumatol Int"},{"key":"2023122314260824800_R7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3899\/jrheum.200755","article-title":"Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases","volume":"48","author":"Bachiller-Corral","year":"2021","journal-title":"J Rheumatol"},{"key":"2023122314260824800_R8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2020-217984","article-title":"Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Freites Nu\u00f1ez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R9","first-page":"748","article-title":"COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)","volume":"38","author":"Scir\u00e8","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2023122314260824800_R10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R11","first-page":"2003","article-title":"Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: results of a nation-wide JCR COVID-19 registry in Japan","volume":"1","author":"Oku","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023122314260824800_R12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study","volume":"73","author":"D\u2019Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023122314260824800_R13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","article-title":"High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study","volume":"40","author":"Loarce-Martos","year":"2020","journal-title":"Rheumatol Int"},{"key":"2023122314260824800_R14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2023122314260824800_R18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/annrheumdis-2020-218310","article-title":"Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","volume":"80","author":"Florence","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","article-title":"Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies","volume":"79","author":"Sanchez-Piedra","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R20","article-title":"Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study","volume":"7","author":"Gracia JM","year":"2021","journal-title":"RMD Open"},{"key":"2023122314260824800_R21","first-page":"1","article-title":"Covid-19: risk factors for severe disease and death","volume":"368","author":"Jordan","year":"2020","journal-title":"BMJ"},{"key":"2023122314260824800_R22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"OpenSAFELY: factors associated with COVID-19 death in 17 million patients","volume":"584","author":"Williamson","year":"2021","journal-title":"Nature"},{"key":"2023122314260824800_R23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/art.41567","article-title":"Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician registry","volume":"73","author":"Gianfrancesco","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023122314260824800_R24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023122314260824800_R25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.semarthrit.2020.06.012","article-title":"COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients","volume":"50","author":"Ramirez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023122314260824800_R26","doi-asserted-by":"crossref","DOI":"10.3390\/v14081631","article-title":"Systemic autoimmune diseases in patients hospitalized with COVID-19 in Spain: a nation-wide registry study","volume":"14","author":"Moreno-Torres","year":"2022","journal-title":"Viruses"},{"key":"2023122314260824800_R27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"2023122314260824800_R28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"2023122314260824800_R29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut"},{"key":"2023122314260824800_R30","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023122314260824800_R31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00393-021-01055-7","article-title":"Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2\/COVID-19 pandemic, including recommendations for COVID-19 vaccination","volume":"80","author":"Specker","year":"2021","journal-title":"Z Rheumatol"},{"key":"2023122314260824800_R32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"RBM","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac148\/48454109\/roac148.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/97\/54800055\/roac148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/97\/54800055\/roac148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T14:26:31Z","timestamp":1703341591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/1\/97\/6901922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac148","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2022,12,14]]}}}